HK1143551A1 - Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin - Google Patents
Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatinInfo
- Publication number
- HK1143551A1 HK1143551A1 HK10110187.0A HK10110187A HK1143551A1 HK 1143551 A1 HK1143551 A1 HK 1143551A1 HK 10110187 A HK10110187 A HK 10110187A HK 1143551 A1 HK1143551 A1 HK 1143551A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- complexes
- carboplatin
- phosphaplatins
- platinum
- fas
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 229960004562 carboplatin Drugs 0.000 title abstract 3
- 190000008236 carboplatin Chemical compound 0.000 title abstract 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 4
- 229910052697 platinum Inorganic materials 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 108091023040 Transcription factor Proteins 0.000 abstract 1
- 102000040945 Transcription factor Human genes 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000007062 hydrolysis Effects 0.000 abstract 1
- 238000006460 hydrolysis reaction Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 abstract 1
- 230000000861 pro-apoptotic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95412607P | 2007-08-06 | 2007-08-06 | |
| US97392607P | 2007-09-20 | 2007-09-20 | |
| PCT/US2008/072398 WO2009021082A2 (en) | 2007-08-06 | 2008-08-06 | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1143551A1 true HK1143551A1 (en) | 2011-01-07 |
Family
ID=40342030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK10110187.0A HK1143551A1 (en) | 2007-08-06 | 2010-10-29 | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7700649B2 (xx) |
| EP (2) | EP2668949A1 (xx) |
| JP (2) | JP5385274B2 (xx) |
| CN (1) | CN101801369B (xx) |
| CY (1) | CY1115504T1 (xx) |
| DK (1) | DK2173337T3 (xx) |
| ES (1) | ES2495743T3 (xx) |
| HK (1) | HK1143551A1 (xx) |
| HR (1) | HRP20140808T1 (xx) |
| PL (1) | PL2173337T3 (xx) |
| PT (1) | PT2173337E (xx) |
| SI (1) | SI2173337T1 (xx) |
| WO (2) | WO2009021082A2 (xx) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2173337T3 (pl) | 2007-08-06 | 2014-11-28 | Univ Ohio | Fosfaplatyny i ich zastosowanie w leczeniu raków opornych na cisplatynę i karboplatynę |
| ES2606855T3 (es) * | 2010-06-04 | 2017-03-28 | Ohio University | Fosfaplatinos y su uso para el tratamiento de cánceres |
| JP2014502634A (ja) * | 2011-01-12 | 2014-02-03 | オハイオ ユニバーシティー | 抗血管新生、抗転移、及びアポトーシス促進の特性を有するホスファプラチン並びにそれらの使用 |
| CN103635525B (zh) | 2011-07-08 | 2016-09-14 | 陶氏环球技术有限责任公司 | 适合用于吹塑膜的聚乙烯共混物组合物，生产它的方法，和由其制备的膜 |
| MX357865B (es) | 2011-10-05 | 2018-07-25 | N Bose Rathindra | Procedimientos eficientes para preparación a gran escala de agentes antitumorales de fosfaplatinos. |
| WO2013052839A1 (en) | 2011-10-05 | 2013-04-11 | Bose Rathindra N | Efficient processes for large scale preparation of phosphaplatins antitumor agents |
| CA2852274C (en) | 2011-10-20 | 2019-08-06 | Nerium Biotechnology, Inc. | Therapeutic combination comprising an extract from nerium for the treatment of cancer |
| ES2619412T3 (es) | 2012-05-24 | 2017-06-26 | Phosplatin Therapeutics Llc | Métodos de síntesis y de purificación para compuestos de fosfaplatino y usos de los mismos |
| US9333211B2 (en) * | 2013-02-22 | 2016-05-10 | University Of Houston System | Phosphaplatin mediated modulation of pigment epithelial derived factor and uses thereof |
| US20150231151A1 (en) * | 2014-02-19 | 2015-08-20 | University Of Houston System | Compositions and methods for the treatment of neurodegenerative diseases |
| EP3154541A4 (en) | 2014-06-11 | 2017-12-20 | Board of Regents, The University of Texas System | Texaphyrin-pt(iv) conjugates and compositions for use in overcoming platinum resistance |
| WO2017116356A1 (en) | 2015-12-30 | 2017-07-06 | Atilim Universitesi | Dna targeted mono and heterodinuclear complexes |
| JP7023968B2 (ja) * | 2017-01-06 | 2022-02-22 | フォスプラティン・セラピューティクス・インコーポレーテッド | 骨がんまたは血液がんの治療のための治療薬としてのホスファプラチン化合物 |
| WO2019051246A1 (en) * | 2017-09-08 | 2019-03-14 | Phosplatin Therapeutics Llc | PHOSPHAPLATINE COMPOUNDS AS IMMUNOMODULATORS AND THERAPEUTIC USES THEREOF |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291027A (en) * | 1979-03-07 | 1981-09-22 | Engelhard Minerals & Chemicals Corp. | Method for treating tumors with ethylenediamine platinum (II) and 1,2-diaminocyclohexane-platinum (II) pyrophosphate complexes |
| US4234500A (en) * | 1979-03-07 | 1980-11-18 | Engelhard Minerals & Chemicals Corporation | Ethylenediamine platinum(II) and 1,2-diamino-cyclohexane platinum(II) pyrophosphate complexes |
| CA2017739A1 (en) * | 1989-07-18 | 1991-01-18 | Leslie S. Hollis | Cis-diamineplatinum complexes with methanediphosphonate and substituted methanediphosphonate ligands as antitumor agents |
| JP4463274B2 (ja) * | 2003-06-27 | 2010-05-19 | 明 小谷 | ビスホスホネート錯体 |
| EP2177525A1 (en) * | 2007-07-06 | 2010-04-21 | TMRC Co., Ltd. | Metal complex compound, cancer therapeutic composition comprising the metal complex compound as active ingredient, and intermediate for production of the metal complex compound |
| PL2173337T3 (pl) | 2007-08-06 | 2014-11-28 | Univ Ohio | Fosfaplatyny i ich zastosowanie w leczeniu raków opornych na cisplatynę i karboplatynę |
-
2008
- 2008-08-06 PL PL08797320T patent/PL2173337T3/pl unknown
- 2008-08-06 WO PCT/US2008/072398 patent/WO2009021082A2/en active Application Filing
- 2008-08-06 ES ES08797320.2T patent/ES2495743T3/es active Active
- 2008-08-06 DK DK08797320.2T patent/DK2173337T3/da active
- 2008-08-06 WO PCT/US2008/072397 patent/WO2009021081A2/en not_active Application Discontinuation
- 2008-08-06 SI SI200831280T patent/SI2173337T1/sl unknown
- 2008-08-06 EP EP13182512.7A patent/EP2668949A1/en not_active Withdrawn
- 2008-08-06 PT PT87973202T patent/PT2173337E/pt unknown
- 2008-08-06 JP JP2010520294A patent/JP5385274B2/ja active Active
- 2008-08-06 EP EP08797320.2A patent/EP2173337B1/en active Active
- 2008-08-06 US US12/187,376 patent/US7700649B2/en active Active
- 2008-08-06 CN CN2008801015774A patent/CN101801369B/zh active Active
-
2010
- 2010-03-11 US US12/722,189 patent/US8034964B2/en active Active
- 2010-10-29 HK HK10110187.0A patent/HK1143551A1/xx unknown
-
2011
- 2011-08-30 US US13/221,458 patent/US8445710B2/en active Active
-
2013
- 2013-03-15 US US13/842,885 patent/US8653132B2/en active Active
- 2013-06-07 JP JP2013120309A patent/JP5647300B2/ja active Active
-
2014
- 2014-08-27 CY CY20141100686T patent/CY1115504T1/el unknown
- 2014-08-27 HR HRP20140808AT patent/HRP20140808T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2495743T3 (es) | 2014-09-17 |
| DK2173337T3 (da) | 2014-09-15 |
| JP5647300B2 (ja) | 2014-12-24 |
| PL2173337T3 (pl) | 2014-11-28 |
| JP2013227218A (ja) | 2013-11-07 |
| US20090042838A1 (en) | 2009-02-12 |
| EP2668949A1 (en) | 2013-12-04 |
| CN101801369B (zh) | 2012-09-19 |
| HRP20140808T1 (hr) | 2014-10-24 |
| JP5385274B2 (ja) | 2014-01-08 |
| CN101801369A (zh) | 2010-08-11 |
| US8445710B2 (en) | 2013-05-21 |
| US8034964B2 (en) | 2011-10-11 |
| PT2173337E (pt) | 2014-09-03 |
| SI2173337T1 (sl) | 2014-10-30 |
| EP2173337B1 (en) | 2014-07-30 |
| US8653132B2 (en) | 2014-02-18 |
| CY1115504T1 (el) | 2017-01-04 |
| EP2173337A2 (en) | 2010-04-14 |
| WO2009021081A3 (en) | 2009-05-07 |
| US20100233293A1 (en) | 2010-09-16 |
| US20130237503A1 (en) | 2013-09-12 |
| WO2009021082A3 (en) | 2009-04-23 |
| US7700649B2 (en) | 2010-04-20 |
| US20110313182A1 (en) | 2011-12-22 |
| WO2009021082A2 (en) | 2009-02-12 |
| WO2009021081A2 (en) | 2009-02-12 |
| EP2173337A4 (en) | 2010-10-27 |
| JP2010535803A (ja) | 2010-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1143551A1 (en) | Phosphaplatins and their use in the treatment of cancers resistant to cisplantin and carboplatin | |
| Brabec et al. | Modifications of DNA by platinum complexes: relation to resistance of tumors to platinum antitumor drugs | |
| Wang et al. | Emerging platinum (IV) prodrugs to combat cisplatin resistance: from isolated cancer cells to tumor microenvironment | |
| Zhou et al. | Photothermally triggered copper payload release for cuproptosis‐promoted cancer synergistic therapy | |
| Reedijk | Platinum anticancer coordination compounds: study of DNA binding inspires new drug design | |
| Xiao et al. | A dual-targeting hybrid platinum (IV) prodrug for enhancing efficacy | |
| Tabassum et al. | Synthesis and characterization of Cu (II)-based anticancer chemotherapeutic agent targeting topoisomerase Iα: In vitro DNA binding, pBR322 cleavage, molecular docking studies and cytotoxicity against human cancer cell lines | |
| EP2796554A3 (en) | Compositions for use in treating BCL2-associated cancers | |
| IL184872A0 (en) | Pyrazole derivatives, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for treatment and prevention of cancers | |
| WO2010132879A3 (en) | Multicomponent degradable cationic polymers | |
| Chin et al. | Synthesis, characterization and biological properties of cobalt (II) complexes of 1, 10-phenanthroline and maltol | |
| MX2010009782A (es) | Tratamientos antitumorales mejorados. | |
| Ramos-Lima et al. | Structural characterization, DNA interactions, and cytotoxicity of new transplatin analogues containing one aliphatic and one planar heterocyclic amine ligand | |
| MX2021008261A (es) | Agentes de rnai para inhibir la expresion de hif-2 a (epas1), composiciones de estos y metodos de uso. | |
| Zanvettor et al. | Copper (II), palladium (II) and platinum (II) complexes with 2, 2-thiophen-yl-imidazole: Synthesis, spectroscopic characterization, X-ray crystallographic studies and interactions with calf-thymus DNA | |
| Miller et al. | Titanium tackles the endoplasmic reticulum: a first genomic study on a titanium anticancer metallodrug | |
| Leung et al. | Epigenetic modulation by inorganic metal complexes | |
| Bostancıoğlu et al. | Studies on the cytotoxic, apoptotic and antitumoral effects of Au (III) and Pt (II) complexes of 1, 10-phenanthroline on V79 379A and A549 cell lines | |
| WO2007089161A3 (en) | DOUBLE HELICAL OLIGONUCLEOTIDES INTERFERING WITH mRNA USED AS EFFECTIVE ANTICANCER AGENT | |
| Orshiso et al. | Biosynthesis of Artemisia abyssinica leaf extract-mediated bimetallic ZnO–CuO nanoparticles: antioxidant, anticancer, and molecular docking studies | |
| WO2015081117A3 (en) | Therapeutic metal complexes | |
| Farias et al. | Cytotoxicity of xyloglucan from Copaifera langsdorffii and its complex with oxovanadium (IV/V) on B16F10 cells | |
| Zorbas-Seifried et al. | DNA interactions of pH-sensitive, antitumor bis (aminoalcohol) dichloroplatinum (II) complexes | |
| Ou et al. | Synthesis and G-quadruplex-binding properties of cationic platinum (II) terpyridine complexes containing σ-alkynyl auxiliaries | |
| Kim et al. | Genome-wide CRISPR Screen Reveal Targets of Chiral Gold (I) Anticancer Compound in Mammalian Cells |